Zealand Pharma A/S
Zealand Pharma A/S is a Danish biopharmaceutical company focused on discovering and developing peptide-based medicines. Its portfolio centers on drug candidates for metabolic and gastrointestinal diseases, with programs advanced through internal R&D and collaboration agreements.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueClinical and preclinical peptide-based medicines for metabolic and gastrointestinal diseases.
Upfront, milestone, and cost-reimbursement revenue from partner agreements.
Capitalized rights to co-develop or commercialize partnered drug candidates.
Customers
Zealand Pharma sells primarily to pharmaceutical partners rather than end patients, with value created through licensing, co-development, and milestone-bearing collaboration agreements. Its commercial counterparties are large biopharma companies that fund development, share costs, and may commercialize products after approval. The underlying end markets are patients and healthcare systems that use treatments for obesity and other chronic metabolic conditions.
Buy development rights, share costs, and pay milestones for Zealand's peptide programs.
Access specific assets and commercialization rights under structured agreements.
Patients treated with approved obesity or gastrointestinal therapies developed from the pipeline.
Strategy
Zealand Pharma's strategy is centered on advancing peptide medicines through partnered development, which allows it to share cost, scientific risk, and commercial upside. The Roche collaboration shows the importance of building combination products and milestone-rich agreements that can fund pipeline advancement and broaden eventual commercialization potential.
Late-stage clinical progress is essential for future milestones, approvals, and commercial value.
Partnerships provide funding, validation, and access to commercialization infrastructure.
Structured payments diversify funding and create upside tied to clinical and sales success.
Geography
The company is headquartered in Denmark and operates as a global biopharma developer through international collaborations rather than a broad manufacturing footprint. Its reported revenue exposure is shaped by partnership agreements that can generate royalties and milestones across the U.S., Europe, and other markets. Geography matters mainly through where partners commercialize products and where development activities, payments, and currency exposures arise.
Risks
The business is highly dependent on clinical success, regulatory outcomes, and partner execution, so setbacks can materially affect future revenue and asset values. It also faces concentration risk in a small number of collaboration agreements, together with foreign exchange and valuation risk from milestone structures, derivative contracts, and capitalized intangible assets.
- Partner concentrationImpact: HighLikelihood: High
A large share of economics is tied to a limited number of collaboration agreements.
Exposure: Roche and other strategic partners
- Clinical development failureImpact: HighLikelihood: Medium
Pipeline value depends on positive trial results and progression to later stages.
Exposure: Petrelintide and other development programs
- Intangible asset impairmentImpact: HighLikelihood: Medium
Capitalized license rights depend on continued clinical and commercial viability.
Exposure: CT-388 license rights and related development assets
- Foreign exchange volatilityImpact: MediumLikelihood: High
Milestones and receivables are linked to USD amounts while reporting is in DKK.
Exposure: USD milestone receipts and FX forwards
Accounting
Judgemental itemsUpfront payments, milestones, and reimbursed development costs follow different recognition patterns.
Impact: Can create large, uneven revenue recognition across periods
License installments for CT-388 are recorded as intangible assets as contractual payments become due.
Impact: Affects balance sheet size and future impairment risk
FX forwards and warrant-related instruments are remeasured through earnings.
Impact: Introduces volatility in financial items
Development milestones and cost-sharing balances may be invoiced later than recognition.
Impact: Affects working capital and reported revenue timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Last updated: 24/10/2026